China Securities Journal, China Securities Network (Wang Luo) — Recently, the award ceremony for the "19th Pharmaceutical Development Award" was held in Beijing. Liu Jiankai, Director and Vice President of Kangtai Biological, and Executive Deputy General Manager of Beijing Minhai Biotechnology Co., Ltd. (hereinafter referred to as "Minhai Biological"), received the "Outstanding Achievement Award." It is understood that the Pharmaceutical Development Award is a medical science prize established in 1994, primarily recognizing outstanding scientific and technological talents who have achieved breakthrough innovative results in the field of medicine and health.

Following the award ceremony, multiple academic exchange sessions were held. Among them, the Vaccine Innovation Forum, themed "Focusing on Frontiers, Interdisciplinary Integration, and Translational Application," was co-organized by Minhai Biological, a wholly-owned subsidiary of Kangtai Biological. The academic event brought together experts including academicians of the Chinese Academy of Engineering, renowned scholars from universities, experts in the medical field, and industry representatives.
During the conference, Zhang Gaiping, an academician of the Chinese Academy of Engineering and a professor at Peking University, delivered an academic presentation titled "My Perspective on Vaccines." Zheng Sujun, Director of the First Department of the Liver Disease Center at Beijing You'an Hospital affiliated with Capital Medical University and doctoral supervisor, and Lin Ang, Director of the Pathogen Diagnosis and Vaccine Technology Innovation Center at China Pharmaceutical University, elaborated on the critical role of hepatitis B vaccines in chronic hepatitis B treatment from the perspectives of clinical application value and R&D innovation progress. Zhang Yuntao, Chief Scientist and Vice President of China National Biotec Group, analyzed the current development status of the global vaccine industry in his report titled "Innovative Development of Chinese Vaccines." He systematically outlined the emerging R&D trends in China's vaccine sector, emphasizing that multivalent combination vaccines remain a key direction for future industry development.

Liu Jiankai shared insights into the technological innovation of the double-carrier 13-valent pneumococcal vaccine and the future direction of pneumococcal vaccine technology. Yin Siyuan, Chief Operating Officer of Chuanxin Biotech, provided a detailed introduction to the research progress of cancer vaccines based on tumor-associated antigens, which sparked in-depth reflection and lively discussion among attending experts and scholars.

It is reported that since its establishment, Minhai Biological has consistently adhered to the mission of "Healthy China" through innovative R&D. The company has undertaken nine national scientific research projects (or tasks) from the Ministry of Science and Technology, the Ministry of Industry and Information Technology, and the National Development and Reform Commission, and has received four provincial and ministerial-level science and technology awards, including the Beijing Science and Technology Progress Second Prize. It has successfully developed, industrialized, and launched 12 vaccine products. Among these, its quadrivalent combination vaccine is the first of its kind in China, and its double-carrier 13-valent pneumococcal conjugate vaccine is the world's first, with the standards for both products subsequently incorporated into the Chinese Pharmacopoeia (Part III). The company has also strategically positioned itself in the forward-looking development of world-first innovative vaccines, such as super-resistant Klebsiella pneumoniae vaccine, a DTaP-Hib-sIPV (pentavalent combination) vaccine, and a Class 1 novel tetravalent inactivated enterovirus vaccine, while already laying the R&D foundation for a DTaP-Hib-sIPV-HepB (hexavalent combination) vaccine.

Minhai Biological stated that this year, the company has also initiated the development of the first vaccine aimed at preventing recurrence in treated hepatitis B patients, marking its official entry into the multi-billion-yuan hepatitis B treatment market. This positions the company to potentially become one of China's leading enterprises covering the entire hepatitis B spectrum—from prevention and treatment to recurrence prevention.

Reference：https://finance.eastmoney.com/a/202512033581387950.html